MAL Daylight Photodynamic Therapy for Actinic Keratosis

Clinical and Imaging Evaluation by 3D Camera

Carmen Cantisani, Giovanni Paolino, Giovanni Pellacani, Dario Didona, Marco Scarno, Valentina Faina, Tommaso Gobello, Stefano Calvieri

Research output: Contribution to journalArticle

Abstract

Non-melanoma skin cancer is the most common skin cancer with an incidence that varies widely worldwide. Among them, actinic keratosis (AK), considered by some authors as in situ squamous cell carcinoma (SCC), are the most common and reflect an abnormal multistep skin cell development due to the chronic ultraviolet (UV) light exposure. No ideal treatment exists, but the potential risk of their development in a more invasive form requires prompt treatment. As patients usually present with multiple AK on fields of actinic damage, there is a need for effective, safe, simple and short treatments which allow the treatment of large areas. To achieve this, daylight photodynamic therapy (DL-PDT) is an innovative treatment for multiple mild actinic keratosis, well tolerated by patients. Patients allocated to the PDT unit, affected by multiple mild-moderate and severe actinic keratosis on sun-exposed areas treated with DL-PDT, were clinically evaluated at baseline and every three months with an Antera 3D, Miravex(©) camera. Clinical and 3D images were performed at each clinical check almost every three months. In this retrospective study, 331 patients (56.7% male, 43.3% female) were treated with DL-PDT. We observed a full clearance in more than two-thirds of patients with one or two treatments. Different responses depend on the number of lesions and on their severity; for patients with 1-3 lesions and with grade I or II AK, a full clearance was reached in 85% of cases with a maximum of two treatments. DL-PDT in general improved skin tone and erased sun damage. Evaluating each Antera 3D images, hemoglobin concentration and pigmentation, a skin color and tone improvement in 310 patients was observed. DL-PDT appears as a promising, effective, simple, tolerable and practical treatment for actinic damage associated with AK, and even treatment of large areas can be with little or no pain. The 3D imaging allowed for quantifying in real time the aesthetic benefits of DL-PDT's increasing compliance.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 11 2016

Fingerprint

Actinic Keratosis
Photodynamic therapy
Photochemotherapy
therapy
Skin
Cameras
cameras
Imaging techniques
evaluation
Skin Pigmentation
Sun
Therapeutics
cancer
clearances
Skin Neoplasms
Solar System
damage
Hemoglobin
lesions
sun

Keywords

  • Aged
  • Aminolevulinic Acid
  • Female
  • Humans
  • Imaging, Three-Dimensional
  • Keratosis, Actinic
  • Light
  • Male
  • Photochemotherapy
  • Photosensitizing Agents
  • Retrospective Studies
  • Severity of Illness Index
  • Journal Article

Cite this

MAL Daylight Photodynamic Therapy for Actinic Keratosis : Clinical and Imaging Evaluation by 3D Camera. / Cantisani, Carmen; Paolino, Giovanni; Pellacani, Giovanni; Didona, Dario; Scarno, Marco; Faina, Valentina; Gobello, Tommaso; Calvieri, Stefano.

In: International Journal of Molecular Sciences, Vol. 17, No. 7, 11.07.2016.

Research output: Contribution to journalArticle

Cantisani, C, Paolino, G, Pellacani, G, Didona, D, Scarno, M, Faina, V, Gobello, T & Calvieri, S 2016, 'MAL Daylight Photodynamic Therapy for Actinic Keratosis: Clinical and Imaging Evaluation by 3D Camera', International Journal of Molecular Sciences, vol. 17, no. 7. https://doi.org/10.3390/ijms17071108
Cantisani, Carmen ; Paolino, Giovanni ; Pellacani, Giovanni ; Didona, Dario ; Scarno, Marco ; Faina, Valentina ; Gobello, Tommaso ; Calvieri, Stefano. / MAL Daylight Photodynamic Therapy for Actinic Keratosis : Clinical and Imaging Evaluation by 3D Camera. In: International Journal of Molecular Sciences. 2016 ; Vol. 17, No. 7.
@article{fbda5ca89cee4e4e9478358cf2db9b85,
title = "MAL Daylight Photodynamic Therapy for Actinic Keratosis: Clinical and Imaging Evaluation by 3D Camera",
abstract = "Non-melanoma skin cancer is the most common skin cancer with an incidence that varies widely worldwide. Among them, actinic keratosis (AK), considered by some authors as in situ squamous cell carcinoma (SCC), are the most common and reflect an abnormal multistep skin cell development due to the chronic ultraviolet (UV) light exposure. No ideal treatment exists, but the potential risk of their development in a more invasive form requires prompt treatment. As patients usually present with multiple AK on fields of actinic damage, there is a need for effective, safe, simple and short treatments which allow the treatment of large areas. To achieve this, daylight photodynamic therapy (DL-PDT) is an innovative treatment for multiple mild actinic keratosis, well tolerated by patients. Patients allocated to the PDT unit, affected by multiple mild-moderate and severe actinic keratosis on sun-exposed areas treated with DL-PDT, were clinically evaluated at baseline and every three months with an Antera 3D, Miravex({\circledC}) camera. Clinical and 3D images were performed at each clinical check almost every three months. In this retrospective study, 331 patients (56.7{\%} male, 43.3{\%} female) were treated with DL-PDT. We observed a full clearance in more than two-thirds of patients with one or two treatments. Different responses depend on the number of lesions and on their severity; for patients with 1-3 lesions and with grade I or II AK, a full clearance was reached in 85{\%} of cases with a maximum of two treatments. DL-PDT in general improved skin tone and erased sun damage. Evaluating each Antera 3D images, hemoglobin concentration and pigmentation, a skin color and tone improvement in 310 patients was observed. DL-PDT appears as a promising, effective, simple, tolerable and practical treatment for actinic damage associated with AK, and even treatment of large areas can be with little or no pain. The 3D imaging allowed for quantifying in real time the aesthetic benefits of DL-PDT's increasing compliance.",
keywords = "Aged, Aminolevulinic Acid, Female, Humans, Imaging, Three-Dimensional, Keratosis, Actinic, Light, Male, Photochemotherapy, Photosensitizing Agents, Retrospective Studies, Severity of Illness Index, Journal Article",
author = "Carmen Cantisani and Giovanni Paolino and Giovanni Pellacani and Dario Didona and Marco Scarno and Valentina Faina and Tommaso Gobello and Stefano Calvieri",
year = "2016",
month = "7",
day = "11",
doi = "10.3390/ijms17071108",
language = "English",
volume = "17",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "7",

}

TY - JOUR

T1 - MAL Daylight Photodynamic Therapy for Actinic Keratosis

T2 - Clinical and Imaging Evaluation by 3D Camera

AU - Cantisani, Carmen

AU - Paolino, Giovanni

AU - Pellacani, Giovanni

AU - Didona, Dario

AU - Scarno, Marco

AU - Faina, Valentina

AU - Gobello, Tommaso

AU - Calvieri, Stefano

PY - 2016/7/11

Y1 - 2016/7/11

N2 - Non-melanoma skin cancer is the most common skin cancer with an incidence that varies widely worldwide. Among them, actinic keratosis (AK), considered by some authors as in situ squamous cell carcinoma (SCC), are the most common and reflect an abnormal multistep skin cell development due to the chronic ultraviolet (UV) light exposure. No ideal treatment exists, but the potential risk of their development in a more invasive form requires prompt treatment. As patients usually present with multiple AK on fields of actinic damage, there is a need for effective, safe, simple and short treatments which allow the treatment of large areas. To achieve this, daylight photodynamic therapy (DL-PDT) is an innovative treatment for multiple mild actinic keratosis, well tolerated by patients. Patients allocated to the PDT unit, affected by multiple mild-moderate and severe actinic keratosis on sun-exposed areas treated with DL-PDT, were clinically evaluated at baseline and every three months with an Antera 3D, Miravex(©) camera. Clinical and 3D images were performed at each clinical check almost every three months. In this retrospective study, 331 patients (56.7% male, 43.3% female) were treated with DL-PDT. We observed a full clearance in more than two-thirds of patients with one or two treatments. Different responses depend on the number of lesions and on their severity; for patients with 1-3 lesions and with grade I or II AK, a full clearance was reached in 85% of cases with a maximum of two treatments. DL-PDT in general improved skin tone and erased sun damage. Evaluating each Antera 3D images, hemoglobin concentration and pigmentation, a skin color and tone improvement in 310 patients was observed. DL-PDT appears as a promising, effective, simple, tolerable and practical treatment for actinic damage associated with AK, and even treatment of large areas can be with little or no pain. The 3D imaging allowed for quantifying in real time the aesthetic benefits of DL-PDT's increasing compliance.

AB - Non-melanoma skin cancer is the most common skin cancer with an incidence that varies widely worldwide. Among them, actinic keratosis (AK), considered by some authors as in situ squamous cell carcinoma (SCC), are the most common and reflect an abnormal multistep skin cell development due to the chronic ultraviolet (UV) light exposure. No ideal treatment exists, but the potential risk of their development in a more invasive form requires prompt treatment. As patients usually present with multiple AK on fields of actinic damage, there is a need for effective, safe, simple and short treatments which allow the treatment of large areas. To achieve this, daylight photodynamic therapy (DL-PDT) is an innovative treatment for multiple mild actinic keratosis, well tolerated by patients. Patients allocated to the PDT unit, affected by multiple mild-moderate and severe actinic keratosis on sun-exposed areas treated with DL-PDT, were clinically evaluated at baseline and every three months with an Antera 3D, Miravex(©) camera. Clinical and 3D images were performed at each clinical check almost every three months. In this retrospective study, 331 patients (56.7% male, 43.3% female) were treated with DL-PDT. We observed a full clearance in more than two-thirds of patients with one or two treatments. Different responses depend on the number of lesions and on their severity; for patients with 1-3 lesions and with grade I or II AK, a full clearance was reached in 85% of cases with a maximum of two treatments. DL-PDT in general improved skin tone and erased sun damage. Evaluating each Antera 3D images, hemoglobin concentration and pigmentation, a skin color and tone improvement in 310 patients was observed. DL-PDT appears as a promising, effective, simple, tolerable and practical treatment for actinic damage associated with AK, and even treatment of large areas can be with little or no pain. The 3D imaging allowed for quantifying in real time the aesthetic benefits of DL-PDT's increasing compliance.

KW - Aged

KW - Aminolevulinic Acid

KW - Female

KW - Humans

KW - Imaging, Three-Dimensional

KW - Keratosis, Actinic

KW - Light

KW - Male

KW - Photochemotherapy

KW - Photosensitizing Agents

KW - Retrospective Studies

KW - Severity of Illness Index

KW - Journal Article

U2 - 10.3390/ijms17071108

DO - 10.3390/ijms17071108

M3 - Article

VL - 17

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 7

ER -